Immune tolerance induction (ITI) with a FVIII concentrate with high VWF content in inhibitor patients with previous unsuccessful ITI and/or negative predictors of ITI response

被引：0
|
作者：
Coppola, A. [1 ]
Arbasi, M. [2 ]
Biasoli, C. [3 ]
Messina, M. [4 ]
Tagliaferri, A. [5 ]
Scaraggi, F. [6 ]
机构：
[1] Federico II Univ Hosp, Reg Reference Ctr Coagulat Disorders, Milan, Italy
[2] Hosp Piacenza, Ctr Bleeding Disorders, Piacenza, Italy
[3] Bufalini Hosp, Transfus & Haemophilia Ctr, Cesena, Italy
[4] Regina Margherita Children Hosp, Paediat Reg Reference Ctr Bleeding & Thrombot Dis, Turin, Italy
[5] Univ Hosp, Reg Reference Ctr Haemophilia, Parma, Italy
[6] Univ Bari, Dept Internal Med, Haemostasis & Thrombosis Ctr, Bari, Italy
来源：
HAEMOPHILIA | 2010年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [21] Continuous infusion of factor IX concentrate for immune tolerance induction (ITI) in two patients with haemophilia B
    Tengborn, L
    Berntorp, E
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS213 - PS213
  • [22] The hemophilia inhibitor genetics study (HIGS): immune tolerance induction (ITI) therapy and outcome
    Astermark, J.
    Menius, E.
    Donfield, S.
    Berntorp, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 562 - 563
  • [23] The use of arteriovenous fistula in inhibitor children improves the feasibility of immune tolerance induction (ITI)
    Mancuso, M.
    Santagostino, E.
    HAEMOPHILIA, 2008, 14 : 55 - 55
  • [24] COSTS AND COST DRIVERS OF IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA AND INHIBITORS
    Bojke, C.
    Botteman, M. F.
    Wilke, C. T.
    Stephens, J. M.
    Kroner, B.
    VALUE IN HEALTH, 2009, 12 (07) : A378 - A379
  • [25] Immune tolerance induction (ITI) in hemophilia A and inhibitors using VWF containing factor VIII concentrates.
    Kreuz, W
    Ettingshausen, CE
    Auerswald, GKH
    Brackmann, HH
    Klingebiel, T
    BLOOD, 2004, 104 (11) : 845A - 845A
  • [26] Immune Tolerance Induction (ITI) in Paediatric and Adult Patients with Haemophilia a (HA) and High-Titre (HT) Factor VIII (FVIII) Inhibitor - Real Life Data
    Letowska, Magdalena Katarzyna
    Zawilska, Krystyna
    Klukowska, Anna
    Chojnowski, Krzysztof
    Zdziarska, Joanna
    Stefanska-Windyga, Ewa
    Windyga, Jerzy
    BLOOD, 2019, 134
  • [27] PROPHYLAXIS WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (FEIBA) IN CHILDREN WITH SEVERE HAEMOPHILIA A (HAEMA) AND HIGH RESPONDING FVIII INHIBITORS BEING ON IMMUNE TOLERANCE INDUCTION (ITI)
    Pergantou, H.
    Komitopoulou, A.
    Xafaki, P.
    Avgeri, M.
    Kapsimali, Z.
    Mazarakakis, M.
    Adamdtziki, E.
    Platokouki, H.
    HAEMATOLOGICA, 2013, 98 : 744 - 745
  • [28] A low-dose immune tolerance induction (ITI) protocol incorporating immunosuppressive agents in haemophilia A children with high-titre factor VIII inhibitor and poor-ITI prognostic risk
    Li, Zekun
    Chen, Zhenping
    Cheng, Xiaoling
    Liu, Guoqing
    Wu, Xinyi
    Li, Gang
    Zhen, Yingzi
    Cai, Siyu
    Poon, Man-Chiu
    Wu, Runhui
    HAEMOPHILIA, 2021, 27 (04) : E469 - E472
  • [29] A retrospective study evaluating immune tolerance induction (ITI) with a plasma-derived factor VIII for patients with hemophilia A and high titer inhibitor
    Escobar, M.
    Sahffer, L.
    Holguin, M.
    McCavit, T.
    Amega, N.
    HAEMOPHILIA, 2019, 25 : 27 - 28
  • [30] Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis
    Oladapo, Abiola
    Novack, Aaron
    Kauf, Teresa
    HAEMOPHILIA, 2016, 22 : 38 - 38
12345